[헬스코리아뉴스 / 박민주] On the 22nd, the Ministry of Food and Drug Safety approved four clinical trials, including researcher tests for ovarian cancer anticancer drugs.
Yonsei University College of Medicine Severance Hospital conducts a researcher’s clinical trial of’Jejula Capsule’ (niopariptosylate monohydrate) at this institution. We will investigate the maintenance therapy of niraparib and bevacizumab in 44 patients with platinum-sensitive recurrent ovarian cancer who have been treated with PARP inhibitors. Jejula Capsule is a medicine used to treat ovarian cancer.
GL Pharmtech conducts a phase 1 clinical trial of’GLK2DS tablets’ (dapagliflozin, sitagliptin) at Vestian Hospital. In 40 healthy adults, the safety and pharmacokinetic characteristics of the dapagliflozin/sitagliptin combination administration alone and the combination administration of a single drug are compared and evaluated.
U&Life Sciences conducts a bioequivalence test that compares its’PA-110′ (finasteride) with MSD Korea’s’Propecia tablet’ (finasteride) on 30 adult male subjects at Bioinfra and Yangji Hospital. Propecia tablet is effective in treating android type alopecia (androgen alopecia).
Chung-Ang University Hospital conducts a researcher’s clinical trial of’Nabota’ (Clostridium botulinum toxin type A) at this institution. In 12 adults in need of improvement of tricephalus hypertrophy, the effective injection point of Nabota was identified, and the improvement effect and safety of tricephalus hypertrophy were evaluated.
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited